Abstract
Over the past decade therapeutic interventions during pregnancy, including the use of drugs, has increased; for example, the prescription use of opioids and nonopioid analgesics for pain management during pregnancy has increased by about 40%. Additionally, women also self-medicate during pregnancy with opioids, and are treated with methadone and buprenorphine which are used as substitution therapy for substance dependence during pregnancy. A nationally representative survey noted that ∼74% of women of reproductive age reported substance use during the previous year, decreasing to ∼ 63% amongst those who were pregnant. Substance dependence was reported by ∼ 20% of women who were not pregnant, and ∼ 15% of those who were pregnant. Understanding the consequences of opioid treatment or dependence during pregnancy requires an investigation of the placental disposition (metabolism and transfer), as well as of the impact of the drugs on the placental function. This review summarizes the research on the placental disposition of opioids and their impact on the placental function.
Keywords: Analgesics, drug abuse, drugs in pregnancy, drug transfer, ex vivo perfusion model, human placenta, narcotics, opioids, substitution therapy, placental disposition
Current Pharmaceutical Biotechnology
Title: Drugs and Medicines in Pregnancy: The Placental Disposition of Opioids
Volume: 12 Issue: 5
Author(s): Antoine Malek and Donald R. Mattison
Affiliation:
Keywords: Analgesics, drug abuse, drugs in pregnancy, drug transfer, ex vivo perfusion model, human placenta, narcotics, opioids, substitution therapy, placental disposition
Abstract: Over the past decade therapeutic interventions during pregnancy, including the use of drugs, has increased; for example, the prescription use of opioids and nonopioid analgesics for pain management during pregnancy has increased by about 40%. Additionally, women also self-medicate during pregnancy with opioids, and are treated with methadone and buprenorphine which are used as substitution therapy for substance dependence during pregnancy. A nationally representative survey noted that ∼74% of women of reproductive age reported substance use during the previous year, decreasing to ∼ 63% amongst those who were pregnant. Substance dependence was reported by ∼ 20% of women who were not pregnant, and ∼ 15% of those who were pregnant. Understanding the consequences of opioid treatment or dependence during pregnancy requires an investigation of the placental disposition (metabolism and transfer), as well as of the impact of the drugs on the placental function. This review summarizes the research on the placental disposition of opioids and their impact on the placental function.
Export Options
About this article
Cite this article as:
Malek Antoine and R. Mattison Donald, Drugs and Medicines in Pregnancy: The Placental Disposition of Opioids, Current Pharmaceutical Biotechnology 2011; 12 (5) . https://dx.doi.org/10.2174/138920111795470859
DOI https://dx.doi.org/10.2174/138920111795470859 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Purine Nucleoside Analogues for Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery The Universal Nature, Unequal Distribution and Antioxidant Functions of Melatonin and Its Derivatives
Mini-Reviews in Medicinal Chemistry Deciphering a Serum Peptide Activity Associated with Biologic Clock
Protein & Peptide Letters Angiogenesis and Microvasculature in the Female Reproductive Organs: Physiological and Pathological Implications
Current Pharmaceutical Design Genome-wide Analysis of Myelodysplastic Syndromes
Current Pharmaceutical Design New Pharmacological Perspectives and Therapeutic Potential of PPAR-γ Agonists
Current Pharmaceutical Design EGF Receptor as a Drug Target in Arterial Hypertension
Mini-Reviews in Medicinal Chemistry PACAP in the Glucose and Energy Homeostasis: Physiological Role and Therapeutic Potential
Current Pharmaceutical Design Antibody Targeting of TGF-β in Cancer Patients
Current Pharmaceutical Biotechnology Is Combined Angiotensin-converting Enzyme Inhibition and Angiotensin Receptor Blockade Associated with Increased Risk of Cardiovascular Death in Hemodialysis Patients?
Current Hypertension Reviews Mechanistic Systems Biology of Inflammatory Gene Expression in Airway Smooth Muscle as Tool for Asthma Drug Development
Current Drug Discovery Technologies Protein Oxidative Modification in the Aging Organism and the Role of the Ubiquitin Proteasomal System
Current Pharmaceutical Design Subject index to volume 3
Current Molecular Medicine Cofactors and Metabolites as Protein Folding Helpers in Metabolic Diseases
Current Topics in Medicinal Chemistry Somatostatin and Octreotide on the Treatment of Acute Pancreatitis - Basic and Clinical Studies for Three Decades
Current Pharmaceutical Design Vesicle Trafficking, Autophagy and Nanoparticles: A Brief Review
Current Nanomedicine Multifaceted Mechanisms for Cell Survival and Drug Targeting in Chronic Myelogenous Leukemia
Current Cancer Drug Targets Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Angiogenic and Vascular Modulation by Extracellular Matrix Cleavage Products
Current Pharmaceutical Design Antiinflammatory Activity of Melatonin in Central Nervous System
Current Neuropharmacology